An interventional study of Nepafenac 0.1% Oph Susp and Nepafenac 0.3% Oph Susp in Pain, sponsored by University Hospital of Patras. Completed at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-04.
Sponsored by University Hospital of Patras · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Pain with a site in Greece — 9 open to participants now, 9 under way, none of them phase 3. Pain · Greece.
Among the 38 studies in Pain with a site in Greece, this one is the 11th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2017, is one of 21 with no phase, and was the 19th registered.
10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →9 of the 38 studies in Pain with a site in Greece are open now. Recruiting first, the newest first:
University of Thessaly · Sites in Greece
Ages 18+
Aristotle University Of Thessaloniki · Sites in Greece
Ages 18–45 · Healthy volunteers
National and Kapodistrian University of Athens · Sites in Greece
Ages 18–80
Dionyssiotis, Yannis, M.D. · Sites in Greece
Ages 20–85 · Healthy volunteers
University of Ioannina · Sites in Greece
Ages 18–75
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 6 · Phase 4 3
First in 2003; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 66 across 8,511 interventional studies indexed under Pain.
Median enrollment 70 across the 31 interventional studies, 87 across the 7 observational. Of the 22 that completed or were terminated, 5 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 38 have an industry lead sponsor. The 10 most frequent:
University Hospital of Patras is the lead sponsor of 43 studies on the registry; 11 are open to participants now.
University Hospital of Patras has 3 studies filed under Pain — fewer than ten, so there is no comparison to draw.
6 of the studies in Pain with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07750327University of West AtticaAn Exercise-based Rehabilitation Program for a Recreational Long-distance Runner With Long-standing Groin Pain | 2026-11-20 |
| NCT07048522University of IoanninaPerioperative Intravenous Nimodipine Trial | 2026-12-19 |
| NCT07306312University of ThessalyPsychological Predictors of Pain and Disability in Patients With Chronic Low Back Pain After Manual Therapy | 2026-12-31 |
| NCT06791044Dionyssiotis, Yannis, M.D.25(OH)-Vitamin D and Its Association With Structural and Functional Parameters in Hospitalized Patients With Neurological Diseases | 2027-06 |
| NCT07901582National and Kapodistrian University of AthensImplementation of a Pain Management Plan in Major Open Abdominal Surgeries. | 2027-09-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 38 studies in Pain with a site in Greece, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The analgestic efffect of Nepafenac 0.1% Eye Drops and Nepafenac 0.3% Eye Drops on pain related to intravitreal injections will be evalutated.
Pain perception will be assessed by the Short Form of the McGill Pain Questionnaire.
Intravitreal injection (IVI) is a preferred route of administration of drugs in the posterior segment of the eye. Intravitreal injection of anti-VEGFs constitutes the mainstay for the treatment of various retinal diseases such as AMD, RVO, DME etc. The procedure of the IVI is, however, associated with a level of discomfort for the patient.
Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the activity of cyclooxygenase-1 and cyclooxygenase-2, and thereby, the synthesis of prostaglandins and thromboxanes. Cyclooxygenase-2 inhibition leads to the anti-inflammatory, analgesic and antipyretic effects of NSAIDs. Ophthalmic NSAIDs constitute an established and effective treatment option for the management of inflammation and pain associated with cataract surgery and of pain associated with corneal refractive surgery, for inhibition of intraoperative miosis and for the treatment of seasonal allergic conjunctivitis.
The primary goal of this study is to assess the analgesic effect of Nepafenac 0.1% and Nepafenac 0.3% Eye Drops on pain related to intravitreal injections immediately after and up to six hours postIVI.
A number of patients scheduled to undergo IVIs of anti-VEGFs will be randomized and divided in three groups. All patients must have already undergone at least one IVI. In patients receiving IVIs in both eyes only one eye will be included in the study.
The patients of the first group will receive Nepafenac 0.1 % Eye Drops 45 minutes prior to the injection.
The patients of the second group will recieve Nepafenac 0.3 % Eye Drop 45 minutes prior to the injection. The patients of the third group will receive Artificial Tears 45 minutes prior to the injection.
Patients will be required to complete the greek version of the short form McGill Pain Questionnaire (SF-MPQ) comprising of the Visual Analogue Scale, the main component of the SF-MPQ and the Present Pain Intensity Scale immediately after the injection and 6 hours post-IVI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One drop of Nepafenac 0.1% will be administered 45' prior to the injection
Drug: Nepafenac 0.1% Oph Susp
One drop of Nepafenac 0.3% will be administered 45' prior to the injection
Drug: Nepafenac 0.3% Oph Susp
One drop of Artificial Tears will be administered 45' prior to the injection
Drug: Artificial tear
One drop of Nepafenac 0.1% will be instilled 45' prior to the IVI.
Also known as: NEVANAC EY.DRO.SUS 1MG/ML
One drop of Nepafenac 0.3% will be instilled 45' prior to the IVI.
Also known as: NEVANAC EY.DRO.SUS 3MG/ML
One drop Artificial Tears will be instilled 45' prior to the IVI.
Also known as: TEARS NATURALE EY.DRO.SOL 0,1%+0,3%
Assessment of topical Nepafenac 0.1% and Nepafenac 0.3% analgesic effect in patients undergoing intravitreal injections of anti-VEGFs
As measured by the Visual Analogue Scale. The Visual Analogue Scale (abbreviation VAS) is a self report pain score chart designed as a 10 cm horizontal line marked at both ends. Each boundary of the line represents the extremes of painful experience (0=no pain and 10= the worst pain ever experienced). The patient is asked to mark on the scale the exact point corresponding to their perception of pain intensity and the score is calculated by measuring from the left hand side to the mark made by the patient, ranging from 0 to 10. Higher scores indicate more severe pain.
Time frame: Immediately after the injection
Assessment of topical Nepafenac 0.1% and Nepafenac 0.3% analgesic effect in patients undergoing intravitreal injections of anti-VEGFs
As measured by the Visual Analogue Scale. The Visual Analogue Scale (abbreviation VAS) is a self report pain score chart designed as a 10 cm horizontal line marked at both ends. Each boundary of the line represents the extremes of painful experience (0=no pain and 10= the worst pain ever experienced). The patient is asked to mark on the scale the exact point corresponding to their perception of pain intensity and the score is calculated by measuring from the left hand side to the mark made by the patient,ranging from 0 to 10. Higher scores indicate more severe pain.
Time frame: Six hours after injection
Assessment of topical Nepafenac 0.1% and Nepafenac 0.3% analgesic effect in patients undergoing intravitreal injections of anti-VEGFs
As measured by the Main Component of the Short Form of the McGill Pain Questionnaire. The main component of the Short form of the McGill Pain Questionnaire (abbreviation SF-MPQ) comprises of 15 adjectives describing the pain experienced (11 sensory and 4 affective). The patient is asked to grade the intensity of each specific pain quality on an intensity scale from 0 to 3 (0= none, 1=mild, 2=moderate, 3=severe). The total score of the main component is derived by adding the rank values given by the patient for each descriptor out of 45. Scores can range from 0 to 45. A higher score of the main component of the SF-MPQ reflects more serious pain.
Time frame: Immediately after the injection
Assessment of topical Nepafenac 0.1% and Nepafenac 0.3% analgesic effect in patients undergoing intravitreal injections of anti-VEGFs
As measured by the Main Component of the Short Form of the McGill Pain Questionnaire. The main component of the Short form of the McGill Pain Questionnaire (abbreviation SF-MPQ) comprises of 15 adjectives describing the pain experienced (11 sensory and 4 affective). The patient is asked to grade the intensity of each specific pain quality on an intensity scale from 0 to 3 (0= none, 1=mild, 2=moderate, 3=severe). The total score of the main component is derived by adding the rank values given by the patient for each descriptor out of 45. Scores can range from 0 to 45. A higher score of the main component of the SF-MPQ reflects more serious pain.
Time frame: Six hours after injection
Assessment of topical Nepafenac 0.1% and Nepafenac 0.3% analgesic effect in patients undergoing intravitreal injections of anti-VEGFs
As measured by the Present Pain Intensity score. The PPI index is a numerical verbal rating scale consisting of 6 adjectives of gradually increasing pain sensation (0, none; 1, mild; 2, discomforting; 3, distressing; 4, horrible; and 5, excruciating). The patient is instructed to choose the adjective indicating their pain state. The score for the PPI is derived from the number next to the patients' adjective of choice, ranging from 0 to 5. Higher scores indicate more intense pain.
Time frame: Immediately after the injection
Assessment of topical Nepafenac 0.1% and Nepafenac 0.3% analgesic effect in patients undergoing intravitreal injections of anti-VEGFs
As measured by the Present Pain Intensity score. The Present Pain Intensity (abbreviation PPI) index is a numerical verbal rating scale consisting of 6 adjectives of gradually increasing pain sensation (0, none; 1, mild; 2, discomforting; 3, distressing; 4, horrible; and 5, excruciating). The patient is instructed to choose the adjective indicating their pain state. The score for the PPI is derived from the number next to the patients' adjective of choice, ranging from 0 to 5. Higher scores indicate more intense pain.
Time frame: Six hours after injection
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Sep 2017 to primary completion in Feb 2018, 5 months.
Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's 5 months is below that.
Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nepafenac
University Hospital of Patras